Bijelic Maja, Djukic Milan, Vukomanovic Vladislav, Parezanovic Vojislav, Lazic Milica, Pavlovic Andrija, Popovic Sasa, Parezanovic Miro, Stefanovic Igor, Djordjevic Stefan, Ninic Sanja, Prijic Sergej, Bozic Cvijan Bojana, Jovanovic Ida, Bajcetic Milica
Department of Cardiology, University Children's Hospital, 11129 Belgrade, Serbia.
Department of Pediatrics, Faculty of Medicine, University of Belgrade, 11129 Belgrade, Serbia.
J Clin Med. 2024 Aug 23;13(17):4976. doi: 10.3390/jcm13174976.
: The angiotensin-converting enzyme inhibitor (ACEI) enalapril is often administered to infants and young children with heart failure (HF) in various dosing regimens and formulations not adapted for their age. : This prospective, two-center, open-label 8-week study evaluated an age-appropriate formulation of orodispersible minitablets (ODMTs) of enalapril (0.25 mg and 1 mg) in children aged 0 to 6 years with HF due to congenital heart disease. An age/weight-based dosing schedule was followed. Measures of echocardiographic parameters, blood pressure, heart rate, modified Ross score, and biochemistry were obtained over the 8-week period. The following two groups were assessed: ACEI-naïve and ACEI-pretreated patients. : In total, 53 children (age range of 0.05 to 4.8 years) were enrolled and 29 were ACEI-naïve. The average enalapril dose was 0.098 mg/kg (0.06-0.17 mg/kg) in the naïve group and 0.15 mg/kg (0.07-0.3 mg/kg) in pretreated patients. After 8 weeks, the modified Ross score and left ventricular diastolic dimension (LVD) z-score showed a significant decrease in both groups ( < 0.005). During 8 weeks follow-up, there were no difference in the z-scores for the systolic blood pressure ( = 0.071) or heart rate ( = 0.146). Pediatric patients treated with ODMTs of enalapril for 8 weeks had favorable improvements in LVD and HF symptoms.
血管紧张素转换酶抑制剂（ACEI）依那普利常以各种未针对婴幼儿年龄调整的给药方案和剂型用于治疗婴幼儿心力衰竭（HF）。
这项前瞻性、双中心、开放标签的8周研究评估了依那普利口腔崩解片（ODMTs，0.25毫克和1毫克）在0至6岁因先天性心脏病导致HF的儿童中的适宜剂型。采用基于年龄/体重的给药方案。在8周期间获取了超声心动图参数、血压、心率、改良罗斯评分和生化指标的测量值。评估了以下两组：未使用过ACEI的患者和曾接受过ACEI治疗的患者。
总共纳入了53名儿童（年龄范围为0.05至4.8岁），其中29名未使用过ACEI。未使用过ACEI的组中依那普利的平均剂量为0.098毫克/千克（0.06 - 0.17毫克/千克），曾接受过治疗的患者中为0.15毫克/千克（0.07 - 0.3毫克/千克）。8周后，两组的改良罗斯评分和左心室舒张内径（LVD）z评分均显著降低（<0.005）。在8周的随访期间，收缩压z评分（=0.071）或心率z评分（=0.146）没有差异。接受依那普利ODMTs治疗8周的儿科患者在LVD和HF症状方面有良好改善。
